Biomanufacturing for clinically advanced cell therapies

Ayesha Aijaz, Matthew Li, David Smith, Danika Khong, Courtney Leblon, Owen S. Fenton, Ronke M. Olabisi, Steven Libutti, Jay Tischfield, Marcela V. Maus, Robert Deans, Rita N. Barcia, Daniel G. Anderson, Jerome Ritz, Robert Preti, Biju Parekkadan

Research output: Contribution to journalReview article

20 Scopus citations

Abstract

The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell immunotherapy, from transplants of engineered haematopoietic stem cells and from other promising cell therapies, an emphasis on biomanufacturing requirements becomes necessary. Robust infrastructure should address current limitations in cell harvesting, expansion, manipulation, purification, preservation and formulation, ultimately leading to successful therapy administration to patients at an acceptable cost. In this Review, we highlight case examples of cutting-edge bioprocessing technologies that improve biomanufacturing efficiency for cell therapies approaching clinical use.

Original languageEnglish (US)
Pages (from-to)362-376
Number of pages15
JournalNature biomedical engineering
Volume2
Issue number6
DOIs
StatePublished - Jun 1 2018

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Computer Science Applications

Cite this

Aijaz, A., Li, M., Smith, D., Khong, D., Leblon, C., Fenton, O. S., Olabisi, R. M., Libutti, S., Tischfield, J., Maus, M. V., Deans, R., Barcia, R. N., Anderson, D. G., Ritz, J., Preti, R., & Parekkadan, B. (2018). Biomanufacturing for clinically advanced cell therapies. Nature biomedical engineering, 2(6), 362-376. https://doi.org/10.1038/s41551-018-0246-6